Borin, M.C., Barbosa, M.M., Pereira, C.O., Martins, C.R., Dos Reis, D.P., Ribeiro, G.J., Tupinambás, J.T., et al. (2023). Budgetary Impact of new label indications after initial drug registration in Brazil: A case study of pembrolizumab and trastuzumab deruxtecan. GHES, 1(1):0994. https://doi.org/10.36922/ghes.0994

Brazilian Ministry of Health. (2012). Diretrizes Metodológicas: Análise de Impacto Orçamentário. Manual para o Sistema de SaúdedoBrasil.Brasília: Secretariat of Science, Technology and Strategic Inputs, Department of Science and Technology.

Brazilian Health Regulatory Agency (ANVISA). (2020). Conceitosand Definições.Available from: https://www.gov. br/anvisa/pt-br/acessoainformacao/perguntasfrequentes/ medicamentos/conceitos-e-definicoes/conceitos-e-definicoes [Last accessed on 2023 Sep 02].

Executive Secretariat of the Drug Market Regulation Chamber (SCMED). (2023). Anuário Estatístico do Mercado Farmacêutico 2022. Available from: https://www. gov.br/anvisa/ptbr/centraisdeconteudo/publicacoes/ medicamentos/cmed/anuario-estatistico-2022-tabelas.xlsx/ view [Last accessed on 2023 Sep 02].

Keytruda. Package Insert. Merck Sharp DohmeFarmacêutica LTDA. Available from: https://consultas.anvisa.gov.br/#/ bulario/q/?nomeproduto=keytruda [Last accessed on 2023 Sep 02].

Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. (2016). Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer.The New England Journal of Medicine, 375(19):1823-1833. https://doi.org/10.1056/NEJMoa1606774

Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Jaime Caro, J., Lee, K.M., Minchin, M., et al. (2014). Budget impact analysis-principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force. Value in Health, 2014;17(1):5-14. https://doi.org/10.1016/j.jval.2013.08.2291